126
Results found
-
Gathering momentum - The Consortium at conferences
Partners in the Pediatric Praziquantel (PZQ) Consortium have maintained a strong presence at international conferences during the last year – communicating progress on development of the pediatric formulation of PZQ. A key goal has been to maintain and develop dialogue with experts and stakeholders in the area of neglected tropical diseases. -
Outstanding contributions to research in Tanzania
In March 2015 the Pediatric Praziquantel Consortium team visited the Republic of Tanzania, spending a week there as part of the efforts towards developing a new child-friendly orodispersible tablet for treating schistosomiasis. -
Schistosomiasis prioritized at meeting in Cameroon
Presentations on schistosomiasis received a great deal of attention at the recent 4th International Congress of the Cameroon Parasitology Society (Bandjoun, 29 April-1 May 2015). The condition was firmly identified as a Neglected Tropical Disease (NTD) that should be better addressed. -
Pediatric Praziquantel Consortium Awarded USD4.9 Million Grant from Global Health Innovative Technology Fund
The second research grant from GHIT provides further support for the Phase II development of a pediatric formulation to combat schistosomiasis in pre-school children -
Satellites track snail disease risk
16-03-2015 Scientists are tracking snails from space in a bid to combat the spread of parasitic disease in Africa. -
European Biopharmaceutical Review publishes case study on Schistosomiasis
Schistosomiasis is one of the most prevalent – yet often neglected – parasitic diseases. -
Consortium wins ‘silver medal’ at 2014 Corporate Engagement Awards
The Pediatric Praziquantel Consortium was shortlisted and won the ‘silver’ medal for ‘best management of a programme’ at the prestigious 2014 Corporate Engagement Awards (CEA). -
Advancing the knowledge on pediatric schistosomiasis
A number of recent lectures and presentations by Drs Kazuhiro Sako (Astellas) and Sonja Skopp (Merck) have helped to raise the profile of the Pediatric Praziquantel Consortium and its efforts to create a new formulation for children younger than 6 years. -
Regulatory approaches: expert meeting in Geneva
Regulators from many different African countries took part in a recent Pediatric Praziquantel Consortium meeting, held in Geneva in October. An intensive two-day agenda encompassed discussions of the entire regulatory approach for the Consortium’s new praziquantel pediatric formulation. -
Regulatory approaches: expert meeting in Geneva
Regulators from many different African countries took part in a recent Pediatric Praziquantel Consortium meeting, held in Geneva in October. An intensive two-day agenda encompassed discussions of the entire regulatory approach for the Consortium’s new praziquantel pediatric formulation. -
Season's Greetings from the Pediatric Praziquantel Consortium
09-12-2014 As the holiday season arrives, we find ourselves reflecting on the past year – and on the inputs from everyone helping to shape the Pediatric Praziquantel Consortium. -
The threat from genital schistosomiasis
We look at the experiences and viewpoints of three experts working with the Pediatric Praziquantel Consortium to help eliminate the genital form of schistosomiasis: Eyrun Kjetland, Jutta Reinhard-Rupp and Peter Hotez. -
ERC consolidator grant winner
Prof. Jennifer Keiser of Swiss Tropical and Public Health Institute (Swiss TPH), partner at the Pediatric Praziquantel Consortium, received a prestigious ‘ERC Consolidator Grant’ from the European Research Council. -
GHIT 1st Anniversary Event – progress to date
The 2014 decision by the Japanese Global Health Innovative Technology Fund (GHIT Fund) to support the Pediatric Praziquantel Consortium was a major milestone. Its ¥186.5 million grant provides crucial support to the Consortium’s clinical development program, by providing funding for phase 1 clinical studies and taste tests. -
Kathleen Ford is named as new Chair
As the Pediatric Praziquantel Consortium moves into the clinical trial stage, the Consortium Board has appointed Mrs. Kathleen Ford, Head of Global Clinical Operations at Merck Serono, as the new Chai